5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one manufacturers
- Lipofermata
-
- $35.00
-
2026-08-27
- CAS:297180-15-5
- Purity: 99.42%
- Supply Ability: 10g
- Lipofermata
-
- $35.00
-
2026-08-04
- CAS:297180-15-5
- Purity: 99.42%
- Supply Ability: 10g
|
| | 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one Basic information |
| Product Name: | 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one | | Synonyms: | 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one;5-bromo-5'-phenyl-3'H-spiro[indole-3,2'-[1,3,4]thiadiazol]-2(1H)-one;CB16.2 aka;Spiro[3H-indole-3,2'(3'H)-[1,3,4]thiadiazol]-2(1H)-one, 5-bromo-5'-phenyl-;5-bromo-5'-phenyl-3'H-spiro[indoline-3,2'-[1,3,4]thiadiazol]-2-one;5-bromo-5'-phenyl-spiro[3H-indole-3,2'(3'H)-[1,3,4]thiadiazol]-2(1H)-one;5-Bromo-5’phenylspiro[1H-indole-3,2’-3H-1,3,4-thiadiazole]-2-one;Lipofermata,Inhibitor,Bacterial,inhibit | | CAS: | 297180-15-5 | | MF: | C15H10BrN3OS | | MW: | 360.23 | | EINECS: | | | Product Categories: | | | Mol File: | 297180-15-5.mol | ![5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one Structure](CAS/20200119/GIF/297180-15-5.gif) |
| | 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one Chemical Properties |
| density | 1.76±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | | solubility | Soluble in DMSO (up to 20 mg/ml). | | form | solid | | pka | 0.44±0.20(Predicted) | | color | Off-white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. | | SMILES | O=C1NC2=CC=C(C=C2C13SC(C4=CC=CC=C4)=NN3)Br |
| | 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one Usage And Synthesis |
| Description | Lipofermata (297180-15-5) is an inhibitor of fatty acid transport protein 2 (FATP2; IC50= 4.84 μM).1It does not inhibit glucose transport or the activity of long chain acyl-CoA synthetase. It prevented palmitate-mediated oxidative stress, induction of BiP and CHOP, and cell death in a dose-dependent manner in hsHepG2 and mINS-1E cells suggesting utility in preventing fatty acid-mediated cell death pathways and lipotoxic disease.2Inhibition was specific for long and very long chain fatty acids but not medium (C6-C10) acids. Lipofermata abrogates lipid transport into melanoma cells and reduces melanoma growth and invasion.3 | | Uses | Lipofermata is a fatty acid transport proteins (FATPs) inhibitor. | | References | [1] ANGEL SANDOVAL . Identification and characterization of small compound inhibitors of human FATP2[J]. Biochemical pharmacology, 2010, 79 7: Pages 990-999. DOI:10.1016/j.bcp.2009.11.008
[2] CONSTANCE AHOWESSO . Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death[J]. Biochemical pharmacology, 2015, 98 1: Pages 167-181. DOI:10.1016/j.bcp.2015.09.004
[3] MAOMAO ZHANG. Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins.[J]. Cancer discovery, 2018, 8 8: 1006-1025. DOI:10.1158/2159-8290.cd-17-1371 |
| | 5-bromo-5'-phenyl-1,2',3,3'-tetrahydrospiro[2H-indole-3,2'-(1,3,4)-thiadiazole]-2-one Preparation Products And Raw materials |
|